First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Kelly JA, Boyle NT, Cole N, Slator GR, Colivicchi AM, Stefanini C, Gobbo OL, Scalabrino GA, Ryan SM, Elamin M, et al.